ORMP - רווח נקי למניה (EPS TTM) Oramed
The absence of debt and an excess of liquid assets allow Oramed Pharmaceuticals (ORMP) to invest consistently in R&D. The 12-month net income per share history confirms this financial foundation, where the parameter value equals 4.07. Business prospects rely on oral insulin delivery systems, although ultimate success depends on regulatory approval and patent protection.
פילוחים אנליטיים ודוחות נתונים של חברת Oramed (ORMP)
Net income per share reflects the portion of equity in the company's total income. This metric is calculated by dividing the total annual profit by the total number of securities. Analyzing net income per share over the last four quarters allows for an assessment of operational efficiency trends. For Oramed Pharmaceuticals (ORMP), this growth depends on optimizing costs for the specialized distribution of insulin products. Controlling logistics expenses directly determines the final yield of each share.
